Slide 1: Q2 2026 Business Update
Nasdaq: PAVM Q2 2026 Business Update August 14, 2026 LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements
Slide 3: Lishan Aklog, M.D., Chairman & CEO
Nasdaq: PAVM Lishan Aklog, M.D. Chairman & CEO
Slide 4: PAVmed Corporate Structure
PAVmed Corporate Structure Nasdaq: PAVM D IAGNOSTIC S D I G I T A L H E A L T H Medical Device Portfolio Nasdaq: LUCD Privately Held Privately Held Early Detection of Esophageal Precancer Digital Cancer Care Platform & Smart Vascular Access Incubator for MedTech Technologies, including PortIO Port a
Slide 5: Recent Highlights: Veris Health
Recent Highlights Veris Health ▪ Commercial phase of OSU strategic engagement accelerating, with patient onboarding steadily increasing ▪ Clinical rollout continuing across additional departments ▪ Implantable physiological monitor development progressing well ▪ Targeting early 2027 FDA 510(k) submi
Slide 6: Recent Highlights: PortIO and Octeris
Recent Highlights PortIO ▪ Positive first-in-human results published in the Journal of Vascular Access, supporting continued advancement of the regulatory strategy ▪ Focused on FDA pre-submission process ▪ Expect to submit FDA pre-submission meeting request in 4Q26 Octeris ▪ Multimodal imaging probe
Slide 7: Q2 2026 Financial Update
Nasdaq: PAVM Q2 2026 Financial Update
Slide 8: Balance Sheet
Balance Sheet ($ in thousands) 2Q26 1Q26 Change Assets Cash $3,784 $6,460 $(2,676) Equity Method Investments (Lucid) $33,494 $35,998 $(2,504) All other Assets $2,936 $2,961 $(25) Liabilities Accounts Payable $1,056 $983 $73 Senior Secured Convertible Notes $15,100 $14,900 $200 Other Liabilities $4,7
Slide 9: P&L
P&L ($ in thousands) 2Q26 2Q25 Change 2Q26 - YTD 2Q25 - YTD Change Revenue + Management Fee Income $3,183 $3,156 $27 $6,355 $6,314 $41 Operating Expenses $7,055 $4,721 $2,334 $15,112 $10,174 $4,938 Net Income (Loss) $(6,598) $(12,324) $5,726 $(7,662) $6,300 $(13,962) EBITDA $(5,629) $(11,903) $6,274
Slide 10: Non-GAAP Operating Expense
Non-GAAP Operating Expense 8,000 7,000 6,000 6,253 6,119 5,904 5,000 4,484 4,392 4,000 3,000 2,000 1,000 0 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our unaudited financial results presented in accordance with U.S. generally a
Slide 11: Q&A
XK PAVmed Nasdaq: PAVM 2 a: Q&A
Slide 12: Closing Remarks
Nasdaq: PAVM Closing Remarks